Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2009

Open Access 01-12-2009 | Primary research

Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid β protein

Authors: Hong Zhao, Jinmin Zhu, Kemi Cui, Xiaoyin Xu, Megan O'Brien, Kelvin K Wong, Santosh Kesari, Weiming Xia, Stephen TC Wong

Published in: Cancer Cell International | Issue 1/2009

Login to get access

Abstract

Background

Cancer and Alzheimer's disease (AD) are two seemingly distinct diseases and rarely occur simultaneously in patients. To explore molecular determinants differentiating pathogenic routes towards AD or cancer, we investigate the role of amyloid β protein (Aβ) on multiple tumor cell lines that are stably expressing luciferase (human glioblastoma U87; human breast adenocarcinoma MDA-MB231; and mouse melanoma B16F).

Results

Quantification of the photons emitted from the MDA-MB231 or B16F cells revealed a significant inhibition of cell proliferation by the conditioning media (CM) derived from amyloid precursor protein (APP) over-expressing cells. The inhibition of U87 cells was observed only after the media was conditioned for longer than 2 days with APP over-expressing cells.

Conclusion

Our results suggest that Aβ plays an inhibitory role in tumor cell proliferation; this effect could depend on the type of tumor cells and amount of Aβ.
Appendix
Available only for authorised users
Literature
1.
Kawas CH, Katzman R: Epidemiology of dementia and Alzheimer disease. Alzheimer Disease. Edited by: Terry RD, Katzman R, Bick KL, Sisodia SS. 1999, Philadelphia, Philly: Lippincott Williams & Wilkins, 95-116. 2
2.
Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT: The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995, 37 (1): 67-73. 10.1002/ana.410370113.CrossRefPubMed
3.
Molsa PK, Marttila RJ, Rinne UK: Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand. 1986, 74 (2): 103-107. 10.1111/j.1600-0404.1986.tb04634.x.CrossRefPubMed
4.
Beard CM, Kokmen E, Sigler C, Smith GE, Petterson T, O'Brien PC: Cause of death in Alzheimer's disease. Ann Epidemiol. 1996, 6 (3): 195-200. 10.1016/1047-2797(95)00068-2.CrossRefPubMed
5.
Yamada M, Sasaki H, Mimori Y, Kasagi F, Sudoh S, Ikeda J, Hosoda Y, Nakamura S, Kodama K: Prevalence and risks of dementia in the Japanese population: RERF's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc. 1999, 47 (2): 189-195.CrossRefPubMed
6.
Selkoe DJ: Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004, 140 (8): 627-638.CrossRefPubMed
7.
Drouet B, Pincon-Raymond M, Chambaz J, Pillot T: Molecular basis of Alzheimer's disease. Cell Mol Life Sci. 2000, 57 (5): 705-715. 10.1007/s000180050035.CrossRefPubMed
8.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297 (5580): 353-356. 10.1126/science.1072994.CrossRefPubMed
9.
Rao KS, Hegde ML, Anitha S, Musicco M, Zucca FA, Turro NJ, Zecca L: Amyloid beta and neuromelanin–toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol. 2006, 78 (6): 364-373. 10.1016/j.pneurobio.2006.03.004.CrossRefPubMed
10.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416 (6880): 535-539. 10.1038/416535a.CrossRefPubMed
11.
Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA: The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides. 2002, 23 (7): 1333-1341. 10.1016/S0196-9781(02)00069-4.CrossRefPubMed
12.
Obrenovich ME, Joseph JA, Atwood CS, Perry G, Smith MA: Amyloid-beta: a (life) preserver for the brain. Neurobiol Aging. 2002, 23 (6): 1097-1099. 10.1016/S0197-4580(02)00038-6.CrossRefPubMed
13.
Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA: Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994, 269 (18): 13623-13628.PubMed
14.
Mattson MP, Pedersen WA: Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci. 1998, 16 (7–8): 737-753. 10.1016/S0736-5748(98)00082-3.CrossRefPubMed
15.
Frederikse PH, Garland D, Zigler JS, Piatigorsky J: Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem. 1996, 271 (17): 10169-10174. 10.1074/jbc.271.17.10169.CrossRefPubMed
16.
Misonou H, Morishima-Kawashima M, Ihara Y: Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry. 2000, 39 (23): 6951-6959. 10.1021/bi000169p.CrossRefPubMed
17.
Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, Zaccheo D, Odetti P, Strocchi P, Marinari UM: Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun. 2000, 268 (2): 642-646. 10.1006/bbrc.2000.2164.CrossRefPubMed
18.
Nakagawa T, Kabuto M, Kubota T, Kodera T, Sato K: Production of amyloid beta protein precursor as a proteinase inhibitor by human astrocytic tumors. Anticancer Res. 1999, 19 (4B): 2963-2968.PubMed
19.
Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF: Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004, 7 (1): 75-85. 10.1023/B:AGEN.0000037335.17717.bf.CrossRefPubMed
20.
Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB: Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999, 274 (36): 25945-25952. 10.1074/jbc.274.36.25945.CrossRefPubMed
21.
22.
Contag CH, Bachmann MH: Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002, 4: 235-260. 10.1146/annurev.bioeng.4.111901.093336.CrossRefPubMed
23.
Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003, 100 (23): 13513-13518. 10.1073/pnas.2235846100.PubMedCentralCrossRefPubMed
24.
Craft N, Bruhn KW, Nguyen BD, Prins R, Liau LM, Collisson EA, De A, Kolodney MS, Gambhir SS, Miller JF: Bioluminescent imaging of melanoma in live mice. J Invest Dermatol. 2005, 125 (1): 159-165. 10.1111/j.0022-202X.2005.23759.x.PubMedCentralCrossRefPubMed
25.
Citron M, Diehl T, Gordon G, Biere A, Seubert P, Selkoe D: Evidence that Ab42 and Ab40 are generated from the b-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA. 1996, 93: 13170-13175. 10.1073/pnas.93.23.13170.PubMedCentralCrossRefPubMed
26.
Xia W, Zhang J, Perez R, Koo EH, Selkoe DJ: Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci USA. 1997, 94 (15): 8208-8213. 10.1073/pnas.94.15.8208.PubMedCentralCrossRefPubMed
27.
Hung AY, Selkoe DJ: Selective ectodomain phosphorylation and regulated cleavage of β-amyloid precursor protein. EMBO J. 1994, 13: 534-542.PubMedCentralPubMed
28.
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ: Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature. 1992, 360: 672-674. 10.1038/360672a0.CrossRefPubMed
29.
Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992, 359 (6393): 325-327. 10.1038/359325a0.CrossRefPubMed
30.
Cui K, Xu X, Zhao H, Wong ST: A quantitative study of factors affecting in vivo bioluminescence imaging. Luminescence. 2008, 23 (5): 292-295. 10.1002/bio.1032.CrossRefPubMed
31.
Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ: Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997, 272 (12): 7977-7982. 10.1074/jbc.272.12.7977.CrossRefPubMed
32.
Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002, 277 (35): 32046-32053. 10.1074/jbc.M201750200.CrossRefPubMed
33.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003, 100 (18): 10417-10422. 10.1073/pnas.1834302100. Epub 12003 Aug 10418PubMedCentralCrossRefPubMed
34.
Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE: Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1–40: a kinetic model. J Protein Chem. 2003, 22 (1): 31-40. 10.1023/A:1023063626770.CrossRefPubMed
35.
Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB: Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA. 2003, 100 (1): 330-335. 10.1073/pnas.222681699.PubMedCentralCrossRefPubMed
36.
Harper JD, Wong SS, Lieber CM, Lansbury PT: Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem & Biol. 1997, 4 (2): 119-125. 10.1016/S1074-5521(97)90255-6.CrossRef
37.
Barrow CJ, Zagorski MG: Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science. 1991, 253 (5016): 179-182. 10.1126/science.1853202.CrossRefPubMed
38.
Mantyh PW, Ghilardi JR, Rogers S, Demaster E, Allen CJ, Stimson ER, Maggio JE: Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem. 1993, 61 (3): 1171-1174. 10.1111/j.1471-4159.1993.tb03639.x.CrossRefPubMed
39.
Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI: Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998, 273 (21): 12817-12826. 10.1074/jbc.273.21.12817.CrossRefPubMed
40.
Klug GM, Losic D, Subasinghe SS, Aguilar MI, Martin LL, Small DH: Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem. 2003, 270 (21): 4282-4293. 10.1046/j.1432-1033.2003.03815.x.CrossRefPubMed
41.
Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, Hartley DM, Selkoe DJ: Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005, 25 (10): 2455-2462. 10.1523/JNEUROSCI.4391-04.2005.CrossRefPubMed
42.
Townsend M, Mehta T, Selkoe DJ: Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007, 282 (46): 33305-33312. 10.1074/jbc.M610390200.CrossRefPubMed
43.
Gschwind M, Huber G: Apoptotic cell death induced by beta-amyloid 1–42 peptide is cell type dependent. J Neurochem. 1995, 65 (1): 292-300.CrossRefPubMed
44.
Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S, Dunlop NM, Wang JM: Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem. 2006, 281 (6): 3651-3659. 10.1074/jbc.M508125200.CrossRefPubMed
45.
Iribarren P, Chen K, Hu J, Gong W, Cho EH, Lockett S, Uranchimeg B, Wang JM: CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1–42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2. Faseb J. 2005, 19 (14): 2032-2034.PubMed
46.
Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, Kim H, Madin A, Hannam JC, Look AT, Kohl N: Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. 2007, 14 (2): 209-219. 10.1016/j.chembiol.2006.12.010.CrossRefPubMed
47.
Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, Schwartz GK: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009, 69 (2): 573-582. 10.1158/0008-5472.CAN-08-2088.PubMedCentralCrossRefPubMed
48.
Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin/{gamma}-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA. 2007, 104 (25): 10613-10618. 10.1073/pnas.0703903104.PubMedCentralCrossRefPubMed
Metadata
Title
Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid β protein
Authors
Hong Zhao
Jinmin Zhu
Kemi Cui
Xiaoyin Xu
Megan O'Brien
Kelvin K Wong
Santosh Kesari
Weiming Xia
Stephen TC Wong
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2009
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-9-15

Other articles of this Issue 1/2009

Cancer Cell International 1/2009 Go to the issue

Primary research

Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model

Primary research

Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis

Primary research

Stimulation of glioma cell motility by expression, proteolysis, and release of the L1 neural cell recognition molecule

Primary research

Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells

Primary research

Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo

Primary research

Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits